BofA raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $145 from $140 and keeps a Buy rating on the shares after the company preannounced Q4 Imcivree revenues of roughly $57M, which was slightly ahead of Street estimates. While the firm notes the press release did not provide color on the growth in number of patients on reimbursed therapy, it expects growth dynamics continue to be stable for the existing Imcivree franchise, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals: Raising Revenue Forecasts and Price Target on Strengthening BBS Growth and Clear aHO Catalyst Path
- Rhythm Pharmaceuticals Reports Strong Preliminary 2025 IMCIVREE Revenue
- Rhythm Pharmaceuticals Sees Q4 IMCIVREE product revenue $57M
- Rhythm Pharmaceuticals announces anticipated upcoming milestones
- Rhythm Pharmaceuticals: Early Promising PWS Data and Robust MC4R Pipeline Support Buy Rating and $140 Target